VelosBio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 30

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.8B

  • Investors
  • 1

VelosBio General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to commit to transforming the lives of patients with cancer by developing therapies targeting ROR1. The company utilizes its ROR1-targeting antibody-based technology to develop a pipeline of ADCs and bispecific antibody product candidates for the treatment of hematologic malignancies and solid tumors, enabling institutions to get novel targeted therapies for use as monotherapy or in combination across a broad range of cancers.

Contact Information

Website
www.velosbio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 11045 Roselle Street
  • Suite 130
  • San Diego, CA 92121
  • United States
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Acquirer
Merck & Co.
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 11045 Roselle Street
  • Suite 130
  • San Diego, CA 92121
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VelosBio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Merger/Acquisition 18-Dec-2020 $2.8B Completed Generating Revenue
5. Early Stage VC (Series B) 02-Jul-2020 Completed Startup
4. Early Stage VC (Series A) 08-May-2020 Completed Startup
3. Early Stage VC 10-Jul-2018 Completed Startup
2. Seed Round 08-Feb-2018 $7.7M $7.7M Completed Startup
1. University Spin-Out 01-Jan-2017 Completed Startup
To view VelosBio’s complete valuation and funding history, request access »

VelosBio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A
Seed 9,625,000 $0.000100 $0.06 $0.8 $0.8 1x $0.8 5.01%
To view VelosBio’s complete cap table history, request access »

VelosBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biopharmaceutical company intended to commit to transforming the lives of patients with can
Pharmaceuticals
San Diego, CA
30 As of 2020

Boston, MA
 

Abingdon, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

VelosBio Competitors (64)

One of VelosBio’s 64 competitors is Compass Therapeutics, a Formerly VC-backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Compass Therapeutics Formerly VC-backed Boston, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
ADC Therapeutics Formerly VC-backed Epalinges, Switzerland
Xenetic Biosciences Corporation Framingham, MA
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
You’re viewing 5 of 64 competitors. Get the full list »

VelosBio Patents

  • 39

    Total Documents Applications and Grants

  • Total Patents Families

  • 13

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

VelosBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4178559-A1 Novel ror1 antibody immunoconjugates Pending 10-Jul-2020
EP-4178559-A4 Novel ror1 antibody immunoconjugates Pending 10-Jul-2020
US-20230293712-A1 Novel ror1 antibody immunoconjugates Pending 10-Jul-2020
WO-2022011075-A1 Novel ror1 antibody immunoconjugates Inactive 10-Jul-2020
WO-2022011075-A9 Novel ror1 antibody immunoconjugates Inactive 10-Jul-2020 A61P35/00
To view VelosBio’s complete patent history, request access »

VelosBio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VelosBio Former Investors (22)

Investor Name Investor Type Holding Investor Since Participating Rounds
ALMA Life Sciences Venture Capital Minority
Adage Capital Management Hedge Fund Minority
Arix Bioscience Venture Capital Minority
Chiesi Ventures Corporate Venture Capital Minority
Citadel Enterprise Americas Hedge Fund Minority
You’re viewing 5 of 22 investors. Get the full list »

Ready to get started?

Request a free trial

VelosBio FAQs

  • When was VelosBio founded?

    VelosBio was founded in 2017.

  • Where is VelosBio headquartered?

    VelosBio is headquartered in San Diego, CA.

  • What is the size of VelosBio?

    VelosBio has 30 total employees.

  • What industry is VelosBio in?

    VelosBio’s primary industry is Pharmaceuticals.

  • Is VelosBio a private or public company?

    VelosBio is a Private company.

  • What is the current valuation of VelosBio?

    The current valuation of VelosBio is .

  • What is VelosBio’s current revenue?

    The current revenue for VelosBio is .

  • How much funding has VelosBio raised over time?

    VelosBio has raised $210M.

  • Who are VelosBio’s investors?

    ALMA Life Sciences, Adage Capital Management, Arix Bioscience, Chiesi Ventures, and Citadel Enterprise Americas are 5 of 22 investors who have invested in VelosBio.

  • Who are VelosBio’s competitors?

    Compass Therapeutics, Adaptimmune Therapeutics, ADC Therapeutics, Xenetic Biosciences, and Alaunos Therapeutics are some of the 64 competitors of VelosBio.

  • When was VelosBio acquired?

    VelosBio was acquired on 18-Dec-2020.

  • Who acquired VelosBio?

    VelosBio was acquired by Merck & Co..

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process